drugset / Trial / NCT00142428
Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma
Phase 2
Completed
30 enrolled
Massachusetts General Hospital
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabBristol-Myers Squibb · collabDana-Farber Cancer Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to begin to collect information and to try to learn whether or not cetuximab works in treating patients with unresectable or metastatic hepatocellular carcinoma.
Timeline
- Start
- 2005-01
- Primary completion
- 2005-10
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |